Circulating Tumour DNA in Stage 1 to 4 Ovarian Cancer

Not Applicable

Recruiting

• Conditions: Ovarian cancer; Cancer - Ovarian and primary peritoneal

• Registration Number: ACTRN12617001119381
• Lead Sponsor: Walter and Eliza Hall Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-07-31
• Last Update Posted: 16 September 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

1. Patients that have had primary debulking surgery for curatively resected stage I-IV high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. Stage IV patients can only be included in the study if they have had a complete resection of all macroscopic disease with no residual disease.
OR
Patients commencing neoadjuvant chemotherapy for stage I-
III high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. Women must be planned to undergo interim debulking surgery.
2. A representative tumour sample can be made available for molecular testing after surgery or a core biopsy pre neoadjuvant chemotherapy if available.
3. Fit and planned for adjuvant chemotherapy.

Exclusion Criteria

1. History of another primary cancer within the last 3 years,
with the exception of non-melanomatous skin cancer,
carcinoma in situ of the cervix and fully resected stage1a
endometrial cancer
2. Patients with EOC of mucinous subtype and sarcoma
3. Patients with Stage IV disease who have residual disease
4. Patients <18 years

Study & Design

• Study Type: Observational
• Study Design: Not specified